ArticleJHEP reports : innovation in hepatology2025
ECM1 expression in chronic liver disease: Regulation by EGF/STAT1 and IFNγ/NRF2 signalling.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Differential and Combined Therapeutic Effects of Mesenchymal Stem Cells and Glutathione on Methotrexate-Induced Mucositis.Journal of biochemical and molecular toxicology · 2026Article
- STAT1 expression in myeloid cells restrains murine norovirus-induced hepatitis and fibrosis.bioRxiv : the preprint server for biology · 2026Article
- Recent advances in TGF-β signaling: insights into regulation, pathophysiological function, and clinical translation.Cell regeneration (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: The extracellular matrix protein 1 (ECM1) is essential for liver homeostasis by keeping latent transforming growth factor-beta quiescent. Upon hepatocyte damage, ECM1 is significantly downregulated, facilitating fibrosis and chronic liver disease (CLD) progression. We investigated the mechanism of ECM1 regulation in hepatocytes under pathophysiological conditions. Methods: We used promoter analysis to predict Results: In healthy hepatocytes, epidermal growth factor (EGF)/EGF receptor (EGFR) signalling sustains ECM1 expression through phosphorylating signal transducer and activator of transcription 1 (STAT1) at serine727 (S727), thus enhancing its binding to the Conclusions: EGF/STAT1 signalling promotes whereas IFNγ/NRF2 inhibits ECM1 expression in hepatocytes in health or disease, respectively. ECM1 has the potential to be developed as an antifibrotic agent, particularly in inflammation- or reactive oxygen species-driven CLD. Impact and implications: This study reveals the regulatory mechanism of ECM1 in hepatocytes, demonstrating that EGF/STAT1 maintains ECM1 expression to prevent fibrosis, whereas IFNγ/NRF2 signalling inhibits ECM1 during chronic liver inflammation, thereby accelerating disease progression. These findings are important for researchers and clinicians to understand the pathogenesis of liver fibrosis, especially in CLD driven by inflammation or oxidative stress. Clinically, ECM1 levels correlate positively with EGFR expression and negatively with IFNγ/NRF2 activation, providing potential antifibrotic targets for CLD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.